Health-related quality of life (HRQOL) in leukemia and lymphoma patients treated with high-dose chemotherapy followed by allogeneic (SCT) and autologous (ASCT) stem cell transplantation or receiving combination chemotherapy (CT) was prospectively assessed by the EORTC QLQ-C30 and compared with reference data from a general population sample. One year after transplant, the SCT group had functional scores which were close to population values except for lower social (P Ͻ 0.0001) and role function (P = 0.0004). More symptoms and problems were reported, especially appetite loss (P = 0.001) and financial difficulties (P = 0.0001). The ASCT patients reported a less than optimal HRQOL relative to the population 1 year post transplant. Cognitive, physical, role, and social function, dyspnoea, financial difficulties and global quality of life were most impaired (P Ͻ 0.001). In the CT group, physical, role and social function, dyspnoea and financial difficulties were impaired 1 year after start of chemotherapy, compared with the general population (P Ͻ 0.001). The EORTC QLQ-C30 was supplemented by a high-dose chemotherapy module, the HDC-19, at the 1-year assessment, but no consistent differences were found across groups. Fifteen to 34% of the patients expressed fears of relapse and worries about future health, while 24-30% indicated no participation in sexual activities. Keywords: health-related quality of life; high-dose chemotherapy; stem cell transplantation; treatment sideeffects; reference data; EORTC QLQ-C30 Some studies evaluating health-related quality of life (HRQOL) in cancer patients treated with high-dose chemotherapy (HDC) followed by allogeneic bone marrow or blood stem cell transplantation (SCT) or reinfusion of autologous bone marrow or blood stem cells (ASCT) have used generic HRQOL questionnaires. Those that possess suf- The SF-36 was employed in a Canadian cross-sectional study of 231 SCT patients at a median time of 40 months post transplant (range 1-253). 4 Compared with the general American population, the patients had significantly lower scores for physical and social function, role-emotional and role-physical function and general health, deviating with 5 to 30 on the 0 to 100 scales. A Spanish study used the NHP to assess HRQOL in a cross-sectional sample of 117 SCT and ASCT patients with a median follow-up of 55 months (range 6-154).
ficient responsiveness to detect changes over time and also provide reference data from the general population such as the Sickness Impact Profile (SIP), 1 the SF-36 2 and the Nottingham Health Profile (NHP), 3 may give important information about acute and late treatment side-effects and about the situation of cancer survivors relative to other people.
The SF-36 was employed in a Canadian cross-sectional study of 231 SCT patients at a median time of 40 months post transplant (range 1-253). 4 Compared with the general American population, the patients had significantly lower scores for physical and social function, role-emotional and role-physical function and general health, deviating with 5 to 30 on the 0 to 100 scales. A Spanish study used the NHP to assess HRQOL in a cross-sectional sample of 117 SCT and ASCT patients with a median follow-up of 55 months (range 6-154). 5 Lack of energy and problems related to work, sexuality and physical mobility were more prevalent than reported from a British general population sample. The only prospective study employing a generic HRQOL tool showed that 39% of the 67 patients had a pre-transplant overall SIP score which was at least 1 standard deviation above the general population mean, indicating impaired functioning. 6 The EORTC QLQ-C30 7 is a cancer-specific questionnaire and might be more suitable for cancer populations than generic questionnaires, since it focuses on problems commonly experienced by cancer patients. Specific problems pertaining to the cancer diagnosis or treatment can be addressed by supplementary questions or modules, as advocated by the EORTC Quality of Life Study Group. 8 The EORTC QLQ-C30 has been employed in one prospective 9 and one cross-sectional study, 10 where patients were retrospectively asked to compare their HRQOL before and after treatment. A small sample of 12 ASCT patients perceived their HRQOL and physical and psychosocial functioning 8-12 months post transplant to be as good as before transplant, 9 while 74% of 125 long-term SCT and ASCT survivors who were a mean of 10 years from transplant reported their current quality of life (QOL) to be the same as or better than before transplant. 10 We have previously reported data on HRQOL from a Norwegian prospective study including SCT and ASCT patients, and lymphoma patients receiving combination chemotherapy (CT). 11 Distinct baseline differences in mean scores of the EORTC QLQ-C30 were found, with better functional status and less symptomatology in SCT patients than in the other two groups. A change in scores was seen during the 1 year of follow-up, with an overall improvement in the ASCT and CT groups towards better functional status and fewer symptoms, while there were no significant differences in the SCT group. The potentially curative aspect of HDC makes it important to prospectively evaluate the patients' prospects regarding returning to prior activities and experiencing a HRQOL comparable to that of other people of similar age and nationality. Thus, the objective of this report is to compare the HRQOL at baseline and 1 year after transplant (SCT and ASCT groups) or start of chemotherapy (CT group) with reference data from a general Norwegian population sample. Furthermore, we report results from a treatment-specific module at the 1-year assessment to provide information about specific side-effects from intensive chemotherapy in more detail.
Patients and methods

Patients
The eligibility criteria required a diagnosis of leukemia or malignant lymphoma, age у16 years, capability of filling in the questionnaires, no present psychiatric disorder, and no prior history of cancer. The inclusion started in April 1993 and lasted for 3 years. All consecutive leukemia patients admitted for high-dose chemotherapy (HDC) followed by allogeneic bone marrow or blood stem cell transplantation (SCT) at the National Hospital (NH) were invited to participate. All consecutive patients with Hodgkin's disease (HD) or non-Hodgkin's lymphoma (NHL) treated with HDC and reinfusion of autologous bone marrow or blood stem cells (ASCT) at the Norwegian Radium Hospital (NRH) were included. At the same time, all patients who were admitted to the NRH for diagnostic verification and start of initial treatment with combination chemotherapy after being diagnosed with HD or NHL, were invited to participate to serve as a reference group (CT group).
The sample of 177 adult cancer patients included in this report was divided into three groups ( Table 1 ). The SCT group encompassed 41 leukemia patients from the NH, while the ASCT group and the CT groups consisted of 51 and 85 patients from the NRH, respectively. The majority of the leukemia patients (61%) suffered from chronic myelogenous leukemia. A significantly higher proportion of the SCT patients were in first complete remission (including CML chronic phase) compared with the ASCT patients (80% vs 20%, P Ͻ 0.0001). Thirty-nine percent of the SCT patients had received combination chemotherapy prior to the conditioning regimens, compared with all ASCT patients. Total body irradiation (TBI) was not used in the SCT group, but given to 34 ASCT patients (67%) at 13 Gy in 10 fractions. Thirteen ASCT patients (29%) had received radiotherapy as part of the primary treatment, compared with none in the SCT group. The conditioning regimen used in the SCT patients consisted of cyclophosphamide (60 mg/kg × 2) and busulphan (4 mg/kg × 4). Thirty-four ASCT patients (67%) received cyclophosphamide (60 mg/kg × 2), while the remaining 17 patients were treated with BEAC: busulphan (300 mg/m The distribution of lymphoma diagnoses was significantly different in the ASCT and CT groups (P Ͻ 0.0001) as expected due to the different indications for treatment across groups. All CT patients received combination chemotherapy, with CHOP: cyclophosphamide, hydroxydaunorubucin, vincristine, and prednisone being most frequently used (35%). Additional radiotherapy was given to 35 patients (41%).
Further details regarding disease and treatment-related variables, patient accrual and compliance from inclusion to 1-year follow-up have been thoroughly described previously.
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Population data
Patients' scores on the EORTC QLQ-C30 were compared against reference values from a Norwegian general population survey. 12 This sample, representative of the adult Norwegian population, was based on a random draw of all inhabitants by The Office of the National Register. All participants received the 33-item questionnaire, the EORTC QLQ-C30 (+3), by mail in addition to a questionnaire asking about socio-demographic data and illness and health. This interim version of the EORTC QLQ-C30 contains three additional questions, but is directly comparable to the EORTC QLQ-C30. A total of 1965 people completed the questionnaires, yielding a response rate of 68%. Results from this survey yielded representative data on HRQOL in the total population, divided by gender and 10-year age groups. 12 Data from those of the population sample who were in the same age range as the cancer patients were included in this report.
The EORTC QLQ-C30 and the treatment-specific module
The EORTC QLQ-C30, version 1, was developed by the EORTC Quality of Life Study Group. 7 It has been validated and cross-culturally tested in various cancer populations. The 30-item questionnaire is composed of scales evaluating physical, role, emotional, cognitive and social function, and global quality of life. Three symptom scales evaluate nausea and vomiting, pain and fatigue, while six single items assess financial difficulties, dyspnoea, diarrhea, appetite loss, sleep disturbances and constipation. The response categories are either dichotomous as 'yes' or 'no', with four categories: 'not at all', 'a little', 'quite a bit' or 'very much' or as a modified visual analogue scale going from 1 to 7. All scores were linearly transformed to a 0 to 100 scale.
It is recommended that the EORTC QLQ-C30 core questionnaire is supplemented by questionnaire modules specific to particular cancers or treatments. 8 The development and validation of such modules is a major activity of the EORTC Quality of Life Study Group. Table 1 Disease and treatment related variables The 19-item module which was developed for the purpose of this study, the HDC-19, focused on physiological symptoms and psychological problems which were not covered by the core questionnaire (Table 2) . Relevant items for patients going through intensive chemotherapy and HDC were derived based on extensive literature searches and interviews with patients, oncologists and oncology nurses. The guidelines from the EORTC Quality of Life Study Group for module development were followed, except field testing in a larger population. 8 Phase I included generation of relevant HRQOL issues by means of extensive literature searches and interviews with patients and health care providers. Operationalization of items and formatting with the same four response categories as the core questionnaire constituted phase II, while the provisional module was pilot-tested in 10 patients in phase III. Fifteen questions were negatively phrased, while the three items on sexuality and one concerning perceived social support were positively phrased.
Methods
All patients were interviewed at the time of inclusion for explanation of study objectives and assessment of sociodemographic data. They were given the EORTC QLQ-C30 to be filled in the same day (T1) if they consented to participate. During the follow-up period which lasted until 1 year (T2) after transplant (SCT and ASCT group) or start of chemotherapy (CT group), the EORTC QLQ-C30 and the HDC-19 were distributed by mail eight times to the transplant patients and six times to the CT patients.
Sixty-two of 76 eligible SCT patients, 69 of 85 eligible ASCT patients and 123 of 169 eligible CT patients consented to participate. During follow-up, 13 SCT patients, five ASCT patients and 10 CT patients died, eight SCT, 13 ASCT and 23 CT patients failed to answer. Five CT patients were accepted on to the ASCT program due to relapse or progression. 11 All patients in this report, 41 SCT patients (84%), 51 ASCT patients (80%) and 85 CT patients (79%) completed the questionnaires at baseline (T1) and after 1 year (T2). Attrition of patients and reasons for withdrawal from approach to the 1-year assessment has been described in detail previously. 11 To avoid overlap with our previous report, 11 only the T2 data are presented here.
Data analyses
The module questions were analyzed as for the core questionnaire, calculating mean scores for each item in accordance with the EORTC Manual. 13 The four positively phrased questions were reversed to be consistent with the other items. Higher scores on the functional scales and the global quality of life (QOL) scale of the core questionnaire represent better functioning, while higher scores on the symptom scales and single items and all questions in the HDC-19 indicate more symptoms or problems. As in our previous report, 11 differences of 10 or more on the 0 to 100 scale were regarded as clinically significant 14, 15 and shown to be perceived as moderate to very much change by patients. 15 We have previously shown that SCT and ASCT patients are heterogeneous with respect to medical and treatment-related characteristics which might impact on HRQOL.
11 Thus, we have chosen not to combine these patients into one transplant group, but to perform separate Table 2 Mean item scores and frequencies of problems (%) on the treatment-specific module: the HDC-19© analyses in order to give a better understanding of the HRQOL for each group relative to the population sample. Data from the general population were used without calculating expected scores based on the age and gender distribution as we have advocated previously, 16 due to minor differences between the observed and expected scores. Chisquare, Kruskal-Wallis, Wilcoxon tests for independent samples and ordered logistic regression analyses were used where appropriate, with a 0.01 level of statistical significance to reduce problems associated with multiple testing. * * * * * * * * * * * * * * * * 
Results
Forty-one of 42 SCT patients, 51 of 52 in the ASCT group and 85 of 90 CT patients who still remained in the study, completed the questionnaires after 1 year (T2). Those SCT patients who did not comply with the study until T2, generally reported poorer HRQOL than those who complied, while no such differences were found in the other two groups.
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No significant differences were found with age, gender and living situation (Table 3) between the three patient groups and the general population. Marital status and educational level were unevenly distributed (P values Ͻ0.0001) when comparing the patient groups and the population sample.
HRQOL 1 year after transplant or start of chemotherapy, (T2) Comparisons with the general population
All patient groups had scores closer to those of the general population 1 year after transplant or start of chemotherapy (Figures 1 and 2) , compared with baseline (data not shown). Impaired role and social function and more financial difficulties were reported by all groups, compared with the population (P values from 0.0004 to Ͻ0.0001). The SCT patients also reported more appetite loss (SCT: 14 vs GP: 7, P = 0.001). Eleven SCT patients had chronic graft-versus-host disease (GVHD) at T2, but did not differ signifi- cantly on any scale or item compared with those who had no GVHD. 11 The ASCT patients still had impaired physical function (P Ͻ 0.0001), cognitive function (P Ͻ 0.0002), global QOL (P = 0.009) and more dyspnoea (P Ͻ 0.0001) relative to the general population. The CT group reported more dyspnoea (P Ͻ 0.0001) and impaired physical function (P = 0.0002) compared with the population sample.
There were differences in marital status and level of education between the general population and the patients in our sample. We therefore used ordered logistic regression to explore the importance of these variables as explanatory factors. The results presented above remained unaffected when these two variables were entered as covariates in a regression model.
Gender
Male SCT patients (n = 23, median age 35) reported significantly less fatigue (P = 0.01), and sleep disturbances (P = 0.006) compared with females (n = 18, median age 38). They also had better role (P = 0.002) and social function (P = 0.005), and better global QOL (P = 0.008).
No statistically significant differences were found across genders in the other two groups, 1 year after transplant or start of chemotherapy (CT group).
The HDC-19 module
Statistically significant differences in mean scores were found with sore mouth being more problematic in the SCT group than in the CT group (SCT: 18 vs CT: 7, P = 0.01). The opposite was found with fear of relapse (SCT: 26 vs CT: 41, P = 0.005) and fear of getting a new cancer (SCT: 17 vs CT: 28, P = 0.01), as shown in Table 2 . Dry skin was significantly more problematic in the ASCT group compared with the CT group (33 vs 18, P Ͻ 0.0001).
There were no consistent differences between groups regarding the frequency of patients who answered 'quite a bit' or 'very much' on the questions in the module ( Table 2 ). The percentages on the somatic symptoms ranged from 4 to 15% in the SCT group, from 0 to 22% in the ASCT group and from 5 to 26% in the CT group. Dry mouth was the only symptom reported more frequently in the CT group (26%), than in the SCT and ASCT groups (12% and 14%, respectively). More somatic problems were found in ASCT patients compared with SCT patients with dry skin (SCT: 10 vs ASCT: 20), stiff joints (SCT: 12 vs ASCT: 22) and potency problems (SCT: 4 vs ASCT: 14) in particular, while 12% of the SCT patients were bothered with sore mouth compared with 0% in the ASCT group. Getting cold easily was reported by 20% and 18% in the SCT and ASCT groups respectively compared with only 9% of the CT patients. Dry mouth, dry skin, stiff joints and pain in the muscles or bones were the most frequently reported symptoms across patient groups. Fear of relapse and worries about future health were expressed by 15-34% across the three groups, while 24-31% indicated no participation in sexual activities. The greatest gender differences were found in the SCT group, being 10 or greater for 12 of the 18 questions applicable to both genders (potency problems omitted). Females generally reported more problems, but statistically significant differences were found with more mucus production (M: 4 vs F: 22, P = 0.01) and reduced sexual interest (M: 44 vs F: 67, P = 0.01) only (Figure 3) .
No consistent gender differences were found in the other two groups. Reduced sexual interest however, yielded the greatest differences in the CT group, being more prevalent among females (M: 45 vs F: 66, P = 0.002).
Discussion
Our results from this first prospective study of HRQOL in SCT and ASCT patients assessed by the EORTC QLQ-C30 compared with data from the general population, were consistent with three other reports, 4-6 despite differences in design and methods. One year after transplant, physical, role and social function were significantly impaired compared with the general population. It could be argued that the reason for differences in HRQOL scores between the patient groups and the general population, was due to lower functional levels and more symptomatology in those who were not in complete remission (SCT group: 2, ASCT group: 9, CT group: 23). Separate analyses for those in complete remission at T2, however, showed that financial difficulties, role and physical function were significantly impaired in all patient groups, and that dyspnoea (ASCT and CT groups) and social function (SCT and ASCT groups) were significantly more problematic than in the general population.
These findings should have direct clinical implications. The social workers in the units should actively address the financial situation of the patients, even if this is not a problematic area during the intensive care periods. Such assessment might prevent economical constraints during followup and ensure that the patients get the social benefits and rights they are entitled to.
Realistic information from the staff about the often lengthy rehabilitation periods before resumption of prior activities is important. Retention of social roles has previously been reported as positively associated with perceptions of global QOL. 21 Knowing what to expect might help patients to reduce their frustration about shortcomings in the fulfilment of working and social roles. 22 Before discharge, the community health service should obtain detailed information about the patient's situation, preferably through a liaison person who can be contacted whenever necessary.
There were only small differences in emotional and cognitive function when comparing the patient groups with the general population. Although elevated levels of anxiety and depression have been reported in transplant patients when compared with the general population, 5, 6, 22 it should be kept in mind that our sample mainly consists of survivors who are free of disease. Thus, one should not necessarily expect lower emotional function in this population relative to other people. This is consistent with our previous report of the EORTC reference data when analyzed for different disease groups in the general population. 16 Cognitive impairment such as memory deficits and problems with concentration have been reported, apparently related to TBI. 23, 24 A possible explanation of the relatively little variation in cognitive function in this sample, might be that TBI was administered in the ASCT group only (34 patients, 67%). It could be that a follow-up period of 12 months is too short for cognitive impairment to manifest. Furthermore, the EORTC QLQ-C30 might not possess sufficient sensitivity to properly assess the cognitive dimension, compared with, for example, neuropsychological tests which should be used in further follow-up studies.
It was a little unexpected that there were no statistically significant differences regarding fatigue between patient groups and the population sample. Persisting fatigue is frequently reported in long-term transplant and other cancer survivors, and is described as prohibitive for normal functioning. [4] [5] [6] 9, 10, 22, [25] [26] [27] [28] [29] [30] Two cross-sectional studies which employed the EORTC QLQ-C30 in long-term transplant survivors 10 and survivors of Hodgkin's disease 31 reported mean scores on fatigue of 23 and 29, respectively, the latter being significantly different from healthy controls. Mean scores in the SCT, ASCT and CT groups in this study at T2 were 27, 33 and 28 relative to 29 in the population sample. However, the different methodology in these studies must be considered. There could be a sensitivity problem with the fatigue scale of the EORTC QLQ-C30, consisting of three items only, which might be insufficient to measure this dimension in detail. Fatigue is believed to increase with the passage of time, 30, 31 thus the relatively low mean scores could be due to the short time span from diagnoses and treatment, accentuating the need for extended follow-up.
The high mean scores of dyspnoea in the ASCT and CT groups compared with the general population (P Ͻ 0.0001) was previously interpreted as a result of radiotherapy with mantle and mediastinal fields.
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It is known from patient studies and population surveys that women tend to report more symptoms and problems and lower functional scores than men. 2, 12, 32 We found significant differences in the SCT group only, although the percentage of CML patients was similar across genders. Female SCT patients also reported more problems than male SCT patients on the treatment specific module, while no such consistencies were found in the other groups. Females across groups, however, reported significantly less sexual interest and activity than males, consistent with other reports. 5, 10 Regardless of gender, 24-30% of the patients indicated no participation in sexual activities. Decreased sexual satisfaction and/or activity have been reported in 14-40% of transplant survivors. 5, 10, 21, 23, [33] [34] [35] A consequence of this should be that sexuality-related issues should be addressed when patients are coming for medical follow-up, which we believe is often not the case due to time constraints, inconvenience and incompetence.
Few distinct differences between groups were found on the other questions of the HDC-19, and we did not find the uniform ranking of more problems in the SCT than in the ASCT than in the CT group as reported by Zittoun et al. 35 Nevertheless, the percentages of patients indicating the presence of symptoms or problems seemed fairly high. Comparing our results with those of other questionnaires is difficult due to different formatting of questions and response categories, and because results are not reported as mean scores, but for example as incidence rates, 10 as a severity index, 36 as percentages of respondents indicating other answer categories than 'not at all' 35, 36 or as a global score. 27 Nevertheless, dry skin, dry mouth, sore mouth and stiff joints have been among the most frequently reported symptoms in transplant patients. 10, 27, 34, 35 The percentages of patients indicating somatic problems on items comparable to ours were generally higher in other studies, 10, 27, 35, 36 most probably because percentages were calculated based on those answering 'quite a bit' or 'very much.' The higher mean scores on fear of relapse among ASCT and CT patients compared with SCT patients, could be because the SCT group was recruited at another hospital. Information and follow-up care could play a part in these matters, although difficult to assess.
The number of comparisons performed between subgroups has to be considered when interpreting our results. Small numbers of patients in some of the analyses indicate that differences between subgroups and low P values could be due to chance findings. On the other hand, the data give a good, prospective description of the differences and similarities between the SCT, ASCT and CT groups, and are reason to believe that differences of 10 or above on the 0 to 100 scales are of clinical importance and perceptible by patients. 14, 15 Despite the good compliance rate and the apparently satisfactory validity of the EORTC QLQ-C30 (+3) in our population survey, 12 we do not advocate that this questionnaire should be used for routine assessment of HRQOL in population samples in general, for which more suitable questionnaires exist, such as the SF-36. 2 The EORTC QLQ-C30 is specifically targeted at cancer patients as described in the introduction section. On the other hand, the EORTC QLQ-C30 encompasses several generic questions which assess prevalent symptoms in the general population. Thus, the intention behind obtaining reference data on the EORTC QLQ-C30 from the general population was primarily to establish a guideline in the interpretation of results from patients, as shown in this report, while specific problems were assessed by the HDC-19, treatment-specific module.
Comparisons with population data are a major advantage in prospective studies like this. This elucidates the functional levels and problems experienced by transplant survivors relative to other people, and should have direct clinical implications regarding information and follow-up of patients. Another strength of this study is the limitation of diagnoses to hematolymphoproliferative diseases. Inclusion of large numbers of, for example, breast cancer patients makes it difficult to differentiate between diagnostic-related variables and treatment side-effects if separate sub-group analyses are not performed, as most reports fail to do.
A follow-up period of only 1 year is too short to draw conclusions about when or whether patients can expect to regain a stable, 'near normal' level of functioning. Even though many patients were functioning well after 1 year, readjustment obviously takes longer for some and some areas were particularly problematic compared with the general population. Consequently, we have extended our follow-up period to go beyond 3 years after transplant or start of chemotherapy. At this evaluation, a domain-specific fatigue questionnaire from which we also have data from the general population will be included, in order to examine this dimension in more detail. This assessment might also enable to us evaluate whether previous measures of HRQOL might predict later outcomes, one of the major advantages of undertaking prospective studies. greatly appreciated. The Unit for Clinical Research at the Norwegian Radium Hospital has provided excellent help in constructing the databases. Thanks also to Anne Kirsti Blystad for access to the bone marrow registry. The first author is a research fellow employed by the Norwegian Cancer Society.
